Keyword: Bristol-Myers Squibb
Pfizer, Manhattan’s hometown drug company, has found brand-new digs, and they’ll be quite an improvement over its current 1960s-era HQ.
If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest Opdivo-plus-Yervoy data won't help.
Our readers' nominations for best and worst M&A show dealmaking gambles can pay off—or not. Here's your chance to weigh in.
In one legal expert's view, Johnson & Johnson will continue to take a tough stand against thousands of talc cases.
After 10 years of shifting pharma fortunes, there's a story behind every revenue tally for Merck, Pfizer, Novartis, Bristol-Myers and their peers.
Bristol-Myers Squibb will soon bid farewell to exclusivity on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs.
Pricing, payers, biosims and R&D setbacks have dragged some biopharma stocks, but others are managing to succeed with investors. Which are which?
FiercePharma kept track as the industry launched drugs, made deals, lost patents, shrank, grew, innovated and revolutionized since 2007. Here's how.
Get set for even more competition in the hep C space as AbbVie picked up FDA approval for Mavyret.
During a tough 2016, only three large drugmakers added jobs and five cut them. AbbVie's roster grew the most, followed by Roche and Lilly.